SCHEMBL369484

SCHEMBL369484

c1ccc2[nH]c(-c3ncc4nc[nH]c4n3)nc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 14/20 0.51
RAB9A P51151 14/20 0.51
KDM4E B2RXH2 11/20 0.51
ALDH1A1 P00352 10/20 0.51
SMN1; SMN2 Q16637 8/20 0.51
PKM P14618 5/20 0.51
HSD17B10 Q99714 5/20 0.51
TP53 P04637 4/20 0.51
NPSR1 Q6W5P4 3/20 0.51
ABCB11 O95342 1/20 0.51
ADORA3 P0DMS8 2/20 0.48
ADORA2A P29274 1/20 0.48
ADORA1 P30542 1/20 0.48
GAA P10253 2/20 0.46
METAP2 P50579 3/20 0.46
METAP1 P53582 2/20 0.46
TSHR P16473 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL369487 0.79 NPC1 (0.51) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL680853 0.74 NPC1 (0.45) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL4456673 0.73 NPC1 (0.44) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL30659969 0.72 NPC1 (0.69) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL30659968 0.72 NPC1 (0.69) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL1535707 0.72 NPC1 (0.69) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL4924089 0.71 KDM4E (0.48) NPC1RAB9AKDM4ESMN1; SMN2PKM
SCHEMBL30634854 0.71 NPC1 (1.00) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL172216 0.71 NPC1 (1.00) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL30561047 0.71 NPC1 (1.00) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593455-B1 PURINE COMPOUNDS SELECTIVE FOR I3 P110 DELTA, AND METHODS OF USE HOFFMANN LA ROCHE (CH) 2015-03-18 EP disclosed
EP-2593455-A1 PURINE COMPOUNDS SELECTIVE FOR I3 P110 DELTA, AND METHODS OF USE F.HOFFMANN-LA ROCHE AG (CH) 2013-05-22 EP disclosed
US-8293736-B2 Purine compounds selective for PI3K P110 delta, and methods of use F. HOFFMANN LA ROCHE AG (CH) 2012-10-23 US disclosed
WO-2012007493-A1 PURINE COMPOUNDS SELECTIVE FOR ΡI3Κ P110 DELTA, AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-01-19 WO disclosed
US-20120015931-A1 PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015931-A1 PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE PIK3CA, PIK3CD, PIK3CG NPC1 2853/4885RAB9A 1546/4885KDM4E 3949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.